Virginie Julien

• Advising Chemonics International, Inc., a global sustainable development firm, on its acquisition of D.M.I, a French international development company. 
• Advising Halma, the global group of life-saving technology companies, on the cross-border acquisition of 100% of the shares and voting rights in French-based Lamidey Noury Medical, reinforcing its international footprint between France and England & Wales.
• Advising Pierre Fabre on the sale of the Centre Immunologie Pierre Fabre in Saint-Julien-en-Genevois, together with the R&D activities carried out on this site, to Jubilant Group.
• Advising Stryker, a US medical technology company, in the context of the acquisition of Serf SAS, a medical device manufacturer/seller that is a wholly owned subsidiary of a French company, located near Lyon France.
• Advising Pierre Fabre Group on the acquisition of Vertical Bio, a Basel-based drug discovery and development company incubated by Ridgeline Discovery (Versant Ventures).
• Advising Pierre Fabre on its auction-process sale of multiple manufacturing sites, requiring several carve-outs into a newly incorporated company, followed by the sale of the shares of the new company.
• Advising Pierre Fabre on its contemplated acquisition of the European rights to oncology products owned by a US-UK group, including marketing authorisations, inventories and dedicated employees. This involved an in-depth, multi-jurisdictional strategic analysis comparing two alternative deal structures across corporate, tax, IP, labour, regulatory and antitrust aspects, taking into account the impact of existing financing arrangements.
• Advised the Renault group on its divestment program in Central and Eastern Europe and Northern Europe.
• Advised Société Générale in connection with its plan to set up a joint venture with the Mitsubishi HC Capital group.
• Advising a global group of life-saving technology companies on the acquisition of 100% of the shares and voting rights of Lamidey Noury Medical.
  
   

Team recognitions

• Chambers France – Pharma/Life Sciences – Band 4 – 2025
  “The team have deep knowledge of our industry and a strong track record.”
  “I like the firm's knowledge of the market and our company, their availability and their responsiveness.”
  “The firm answers my needs in terms of cross-practice skills, values and empathy. The lawyers listen to the clients and they are available.”
  “I am satisfied with their interpersonal skills with the client and their ability to be a real business partner.”
• Legal 500 - Industry Focus: Healthcare and Life Sciences - Tier 2 – 2025
  “International firm with extensive expertise. Interest in complex cases requiring varied and highly specialised resources and expertise.”
  “Skills in the health sector and diversity in areas of expertise (litigation, administrative, regulatory).”
  “The team is very cohesive and diligent in implementation. It is very experienced in acquisitions, divestments and industrial contracts in the field of pharmaceuticals and medical devices. It has good international experience and benefits from a competent network in the field, particularly in the US.”
• Legal 500 - Private Equity: LBO - Tier 3 – 2025
  "Availability, in-depth expertise, ability to support both SMEs and large international groups.”
• Legal 500 - Mergers & acquisitions - Tier 4 – 2025
  "Great organisational capabilities combined with a focused professional approach and excellent connections worldwide.”
• Option Droit & Affaires – Mergers & acquisitions – 5 stars – 2025
• Option Droit & Affaires – Private Equity – 5 stars - 2025